Nuwellis
making the standard of care in fluid overload | Nuwellis
Company
Deck Type
Sector
Industry
Deck date
August 2023
Slide
28 of 29
Similar slides by Nuwellis
See diffirences between slides (animation)
Investor Presentation
March 2023
making the standard of care in fluid overload | Nuwellis
Related slides by other companies
Nuvalent
Investor Presentation
January 2024
potential best in class profile for opportunity to both move up the treatment paradigm grow the market with deep durable responses no clear standard of care soc mutation disease current soc of disease demonstrated activity where current available therapies have failed opportunity to supplant standard of care with a differentiated clinical activity observed in heavily patients with who likely exhausted all available therapies including after or with resistance mutations with history of metastasis including intracranial responses to address combined medical needs mutation coverage activity avoiding off target adverse events opportunity to drive deep durable responses favorable preliminary safety consistent with selective sparing design sources sales and forecasts accessed lin precision and lung cancer a | Nuvalent
Nuvalent
Investor Presentation
April 2024
alk and landscape emerging resistance mutations increasing involvement treatment related adverse events limit utility of approved therapies advanced metastatic advanced metastatic notable populations standard of care notable populations wild type domain standard of care alternatives resistance mutation no clear standard of care no clear standard of care nae single resistance compound resistance mutations was approved not approved but in guidelines line line line central nervous system sources lung cancer jama shaw no peters shaw lancet jack cancer res sources lin precision lung cancer i | Nuvalent
Nuvalent
Investor Presentation
January 2024
alk market opportunity meaningful commercial markets with combined sales in potential best in class profiles ana designed with the goal to supplant the current standard of care arrays clinical proof of concept demonstrated in heavily treated patient populations cee lear for patients more durable responses potential to grow the through all a global sales for standard of care months standard of care months other and generally used guidelines for for version | Nuvalent
Nuvalent
Investor Presentation
January 2024
potential best in class profile for opportunity to both move up the treatment paradigm grow the market with deep durable responses no clear standard of care soc mutation disease current soc of disease demonstrated activity where current available therapies have failed opportunity to supplant standard of care with a differentiated clinical activity observed in heavily patients with who likely exhausted all available therapies including after or with resistance mutations with history of metastasis including intracranial responses to address combined medical needs mutation coverage activity avoiding off target adverse events opportunity to drive deep durable responses favorable preliminary safety consistent with selective sparing design sources sales and forecasts accessed lin precision and lung cancer a | Nuvalent
Other recent decks by Nuwellis
See all presentations (2 decks)
Investor Presentation
March 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights